GO:1902999 negative regulation of phospholipid efflux: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1902999 describes any process that stops, prevents, or reduces the frequency, rate, or extent of phospholipid efflux.
• Phospholipid efflux is critical for cholesterol transport and membrane asymmetry, and its negative regulation impacts diseases such as sepsis and cancer [3,4,5].
• Key proteins involved include ABCA1, ABCG1, PLSCR1, and phospholipid flippases such as Lem3 [3,5,6].
• Loss of cardiolipin and porins can bypass essential cell envelope stress responses, linking phospholipid efflux to bacterial survival.
• Zap1 regulates responses to fluconazole in Candida glabrata, highlighting roles in antifungal resistance.
• CRISPR knockout, point mutation, knock-in, and overexpression models enable precise dissection of negative regulation of phospholipid efflux [3,5,6].
Description
Phospholipid efflux is the process by which phospholipids are transported out of cells or membrane leaflets, a fundamental step in cholesterol transport and membrane lipid asymmetry. The Gene Ontology term GO:1902999, negative regulation of phospholipid efflux, encompasses any process that stops, prevents, or reduces the frequency, rate, or extent of this efflux. This regulation is essential for maintaining cellular lipid homeostasis and responding to environmental stresses [3,4]. Dysregulation of phospholipid efflux has been implicated in diverse pathologies, including sepsis, cancer chemoresistance, and fungal pathogenicity [4,5,6]. Understanding the molecular players and regulatory mechanisms is therefore of broad biomedical interest. Researchers studying this process require reliable models to test causality and identify therapeutic targets [3,5].
negative regulation of phospholipid efflux At A Glance
| GO ID | GO:1902999 |
|---|---|
| GO term | negative regulation of phospholipid efflux |
| Ontology | biological_process |
| Synonym | inhibition of phospholipid efflux; downregulation of phospholipid export |
| Major function | Stops, prevents, or reduces phospholipid efflux |
| Related processes | Cholesterol transport, membrane asymmetry, lipid homeostasis |
| Key regulators | ABCA1, ABCG1, PLSCR1, Lem3, Zap1 |
| Disease relevance | Sepsis, cancer chemoresistance, fungal infections |
What Is GO:1902999?
GO:1902999 is a biological process term defined as any process that stops, prevents, or reduces the frequency, rate, or extent of phospholipid efflux. It includes synonyms such as inhibition of phospholipid efflux and negative regulation of phospholipid export. This term is distinct from positive regulation and from the efflux process itself, focusing specifically on inhibitory mechanisms.
Why Is negative regulation of phospholipid efflux Important in Cell Biology?
Negative regulation of phospholipid efflux is crucial for maintaining membrane lipid composition and cellular cholesterol balance. Its dysregulation contributes to sepsis pathophysiology, where high-density lipoproteins and phospholipid efflux are altered. In cancer, PLSCR1 drives chemoresistance in triple-negative breast cancer via mRNA stabilization and EGFR-MAPK activation, linking phospholipid efflux regulation to therapy resistance. In fungi, Lem3 influences Candida albicans pathogenicity through plasma membrane asymmetry, and Zap1 is required for Candida glabrata response to fluconazole. Thus, understanding this process offers insights into infectious diseases, cancer, and metabolic disorders [3,4,5,6,8].
• Maintains cholesterol homeostasis and prevents lipid accumulation.
• Regulates membrane asymmetry and cell surface properties.
• Impacts sepsis outcomes by modulating HDL function.
• Contributes to chemoresistance in triple-negative breast cancer.
• Affects antifungal susceptibility in Candida species.
• Plays a role in bacterial cell envelope stress responses.
• Provides targets for therapeutic intervention in lipid disorders.
• Enables mechanistic studies using CRISPR models [3,5,6].
What Happens During negative regulation of phospholipid efflux?
Initiation of inhibitory signaling
In simple terms: A signal tells the cell to stop exporting phospholipids.
Negative regulation begins when cellular signals activate inhibitory pathways that target phospholipid efflux machinery. For example, in sepsis, inflammatory mediators can alter HDL composition and reduce phospholipid efflux capacity. In cancer, PLSCR1 stabilization via METTL3/IGF2BP3 can enhance EGFR-MAPK signaling, indirectly suppressing efflux.
Modulation of transporter activity
In simple terms: Proteins that pump phospholipids out are turned down.
ABCA1 and ABCG1 are key transporters mediating phospholipid efflux to apolipoproteins. Negative regulation can occur through reduced expression, post-translational modifications, or altered membrane environment that impairs their function. In Candida albicans, Lem3, a flippase subunit, maintains plasma membrane asymmetry; its loss affects efflux-related processes.
Changes in membrane lipid composition
In simple terms: The lipid makeup of the membrane changes to favor retention.
Alterations in cardiolipin and porins can bypass essential cell envelope stress responses in Escherichia coli, indicating that membrane lipid composition directly impacts efflux regulation. Similarly, phosphatidylcholine availability influences cholesterol transport machinery.
Downstream cellular consequences
In simple terms: Stopping efflux leads to lipid buildup and altered cell behavior.
Reduced phospholipid efflux can lead to intracellular lipid accumulation, affecting signaling and survival. In cancer, this may contribute to chemoresistance through sustained EGFR-MAPK activation. In fungi, it impacts pathogenicity and drug response [6,8].
Key Genes Involved in GO:1902999 negative regulation of phospholipid efflux
The following genes and proteins are experimentally implicated in negative regulation of phospholipid efflux or related processes.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ABCA1 | Mediates phospholipid efflux to apoA-I | Target for cholesterol transport studies |
| ABCG1 | Transports phospholipids to HDL | Linked to reverse cholesterol transport |
| PLSCR1 | Phospholipid scramblase, drives chemoresistance | TNBC chemoresistance via METTL3/IGF2BP3 |
| METTL3 | m6A methyltransferase, stabilizes PLSCR1 mRNA | Epitranscriptomic regulation of efflux |
| IGF2BP3 | m6A reader, binds and stabilizes mRNA | Enhances PLSCR1 expression |
| EGFR | Receptor tyrosine kinase, activated by MAPK | Downstream of PLSCR1 in TNBC |
| MAPK | Signaling kinase cascade | Mediates PLSCR1-driven chemoresistance |
| Lem3 | Phospholipid flippase subunit | Maintains membrane asymmetry in C. albicans |
| Zap1 | Zinc-responsive transcription factor | Required for fluconazole response in C. glabrata |
| Cardiolipin synthase | Synthesizes cardiolipin | Loss bypasses sigma E essentiality in E. coli |
| Porins | Outer membrane channels | Loss with cardiolipin bypasses stress response |
| Sigma E | Cell envelope stress response factor | Essentiality bypassed by lipid changes |
| HDL | Lipoprotein particle | Accepts phospholipids; altered in sepsis |
| ApoA-I | Main HDL apolipoprotein | Acceptor for ABCA1-mediated efflux |
| SR-BI | HDL receptor | Influences cholesterol transport |
| CETP | Cholesteryl ester transfer protein | Modulates HDL metabolism |
| LCAT | Lecithin-cholesterol acyltransferase | Esterifies cholesterol on HDL |
| PLTP | Phospholipid transfer protein | Transfers phospholipids between lipoproteins |
How Is negative regulation of phospholipid efflux Regulated?
Negative regulation of phospholipid efflux is controlled at multiple levels. Transcriptional regulation of ABCA1 and ABCG1 by nuclear receptors such as LXR affects efflux capacity. Post-translational modifications, including phosphorylation, can modulate transporter activity. In cancer, m6A modification of PLSCR1 mRNA by METTL3 and IGF2BP3 enhances its stability, indirectly influencing efflux and chemoresistance. In fungi, Zap1 regulates genes required for fluconazole response, which may include lipid efflux components. In bacteria, loss of cardiolipin and porins bypasses the essential sigma E stress response, indicating that membrane lipid environment regulates efflux-related stress pathways.
negative regulation of phospholipid efflux and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PLSCR1 | TNBC chemoresistance | Knockout in TNBC cell lines |
| ABCA1 | Cholesterol transport disorders | Point mutation knock-in in HepG2 |
| Lem3 | Candida albicans pathogenicity | Knockout in C. albicans |
| Zap1 | Candida glabrata fluconazole resistance | Knockout in C. glabrata |
| Cardiolipin synthase | E. coli envelope stress | Knockout in E. coli |
Sepsis and HDL dysfunction
Sepsis alters HDL composition and function, impacting phospholipid efflux and cholesterol transport. Negative regulation of efflux may contribute to impaired reverse cholesterol transport and worse outcomes.
Cancer chemoresistance
In triple-negative breast cancer, PLSCR1 drives chemoresistance via METTL3/IGF2BP3-mediated mRNA stabilization and EGFR-MAPK pathway activation. This highlights how negative regulation of phospholipid efflux can promote therapy resistance.
Fungal infections
Lem3, a phospholipid flippase subunit, influences Candida albicans pathogenicity through maintenance of plasma membrane asymmetry. Zap1 is required for Candida glabrata response to fluconazole, linking lipid regulation to antifungal resistance.
Bacterial stress responses
Loss of cardiolipin and porins bypasses the essentiality of the sigma E cell envelope stress response in Escherichia coli, revealing connections between lipid composition and stress survival.
From negative regulation of phospholipid efflux-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of ABCA1 increase phospholipid efflux? | ABCA1 knockout in macrophages |
| Does PLSCR1 point mutation affect chemoresistance? | PLSCR1 point mutation knock-in in TNBC cells |
| Can Lem3 knockout alter membrane asymmetry? | Lem3 knockout in C. albicans |
| Does Zap1 overexpression rescue fluconazole resistance? | Zap1 overexpression in C. glabrata |
| Does cardiolipin synthase knockout bypass sigma E? | Cardiolipin synthase knockout in E. coli |
| Does METTL3 knockdown reduce PLSCR1 stability? | METTL3 knockout in TNBC cells |
How to Study the negative regulation of phospholipid efflux Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screen | Gene essentiality for efflux | Identify negative regulators |
| RNA-seq | Transcriptional changes | Pathway analysis |
| m6A-seq | m6A modification sites | Epitranscriptomic regulation |
| Lipidomics | Phospholipid species | Membrane composition |
| Proteomics | Protein abundance | Transporter levels |
| Fluorescence microscopy | Membrane asymmetry | Fungal pathogenicity |
| Cholesterol efflux assay | Efflux capacity | HDL function |
| CRISPR activation | Gene overexpression | Rescue experiments |
CRISPR knockout screens
Genome-wide CRISPR knockout screens can identify genes whose loss alters phospholipid efflux, using fluorescent lipid analogs or cholesterol efflux assays [3,5].
RNA-seq and m6A profiling
RNA-seq and m6A-seq can reveal transcriptomic changes and epitranscriptomic regulation of efflux-related genes such as PLSCR1.
Proteomics and lipidomics
Mass spectrometry-based proteomics and lipidomics quantify changes in protein abundance and lipid species upon modulation of efflux regulators [3,6].
Imaging of membrane asymmetry
Fluorescence microscopy with annexin V or lipid probes can visualize plasma membrane asymmetry changes in fungal or mammalian cells.
How CRISPR Can Be Used to Study GO:1902999 negative regulation of phospholipid efflux
Knockout
CRISPR knockout of ABCA1, ABCG1, or PLSCR1 can abolish or reduce phospholipid efflux, enabling causal testing [3,5]. In Candida albicans, Lem3 knockout alters membrane asymmetry and pathogenicity.
Point Mutation
Introducing point mutations in ABCA1 or PLSCR1 can mimic disease-associated variants and dissect domain-specific functions in efflux regulation [3,5].
Knock-in
Knock-in of tagged versions of ABCA1 or PLSCR1 allows live-cell imaging and interaction studies without altering endogenous regulation [3,5].
Overexpression
Overexpression of PLSCR1 or METTL3 can drive chemoresistance and enhance negative regulation of efflux, providing gain-of-function models.
How EDITGENE Supports negative regulation of phospholipid efflux Research
Researchers studying negative regulation of phospholipid efflux-related genes often need to determine whether a candidate gene is causally involved in efflux suppression or is merely correlated. EDITGENE provides comprehensive CRISPR services to generate precisely engineered cell models for such functional studies.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of phospholipid efflux research.
Frequently Asked Questions About negative regulation of phospholipid efflux
What is GO:1902999?
GO:1902999 is the Gene Ontology term for negative regulation of phospholipid efflux, defined as any process that stops, prevents, or reduces the frequency, rate, or extent of phospholipid efflux.
What genes are involved in negative regulation of phospholipid efflux?
Key genes include ABCA1, ABCG1, PLSCR1, METTL3, IGF2BP3, Lem3, and Zap1 [3,5,6,8].
How is phospholipid efflux regulated?
It is regulated transcriptionally, post-translationally, and via epitranscriptomic mechanisms such as m6A modification [3,5].
What diseases are linked to phospholipid efflux?
Sepsis, cancer chemoresistance, and fungal infections are associated with altered phospholipid efflux [4,5,6,8].
What is the role of PLSCR1 in cancer?
PLSCR1 drives chemoresistance in triple-negative breast cancer via METTL3/IGF2BP3-mediated mRNA stabilization and EGFR-MAPK activation.
How does Lem3 affect Candida albicans?
Lem3, a phospholipid flippase subunit, influences pathogenicity through maintenance of plasma membrane asymmetry.
Why is Zap1 important for antifungal resistance?
Zap1 is required for Candida glabrata response to fluconazole, linking zinc homeostasis to drug resistance.
Can CRISPR be used to study phospholipid efflux?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models enable precise functional studies [3,5,6].
What methods measure phospholipid efflux?
Cholesterol efflux assays, lipidomics, and fluorescence microscopy are commonly used [3,4,6].
How does sepsis affect phospholipid efflux?
Sepsis alters HDL composition and function, impacting phospholipid efflux and cholesterol transport.
Conclusion
GO:1902999 negative regulation of phospholipid efflux is a critical biological process with broad implications in metabolism, infection, and cancer [3,4,5,6,8]. Understanding its molecular mechanisms and key regulators provides opportunities for therapeutic intervention. CRISPR-based models are indispensable for dissecting causality and developing targeted strategies [3,5,6].
References
- 3. Lagace TA. 2015. Phosphatidylcholine: Greasing the Cholesterol Transport Machinery.. Lipid Insights 8(Suppl 1):65-73 PMID: 27081313
- 4. Parolini C. 2025. Sepsis and high-density lipoproteins: Pathophysiology and potential new therapeutic targets.. Biochim Biophys Acta Mol Basis Dis 1871(5):167761 PMID: 40044061
- 5. Lu Y et al.. 2026. PLSCR1 drives chemoresistance in TNBC via METTL3/IGF2BP3-mediated mRNA stabilization and EGFR-MAPK pathway activation.. Cell Death Dis 17(1) PMID: 42140933
- 6. Agrawal P et al.. 2026. Lem3, a phospholipid flippase subunit, influences Candida albicans pathogenicity through maintenance of plasma membrane asymmetry.. Microbiol Spectr 14(5):e0296525 PMID: 41914745
- 7. Yang Z et al.. 2025. Loss of cardiolipin and porins bypasses the essentiality of the sigma E cell envelope stress response in Escherichia coli.. mBio 16(9):e0161325 PMID: 40823832
- 8. Gaspar-Cordeiro A et al.. 2022. Zap1 is required for Candida glabrata response to fluconazole.. FEMS Yeast Res 22(1) PMID: 35040997
